Edwards Lifesciences (NYSE:EW) investors have had enough headaches over the recent past. The company's stock has spiraled down, exacerbated by the firm's recent downbeat earnings report that showed sales of its Sapien heart device missing Wall Street's expectations. To bring back investor confidence, the company recently announced a $750 million buyback to help stabilize the stock.

But will that be enough? Edwards is still facing a sluggish medical device market, and with competition rising for its Sapien, this company could be in trouble in coming years. Should you believe in Edwards' buyback plan? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss the merits of this company's latest move -- and what Edwards' future in a tough industry has in store.